## **Amended Claims**

- (Previously presented) A combination preparation, comprising as pharmaceutically active
  ingredients at least one active compound component A and at least one active compound
  component B, characterized in that the active compound component A is a PDE inhibitor, and the
  active compound component B is an antilipemic.
- 2. (Cancelled).
- 3. (Cancelled).
- 4. (Cancelled).
- 5. (Currently amended) The combination preparation as claimed in claim 1, characterized in that the active compound components A and B are present as a functional unit, in particular in the form of wherein said unit is selected from a mixture, a mix or a blend.
- 6. (Currently amended) The combination preparation as claimed in claim 1, characterized in that the active compound components A and B are (spatially) separated, in particular as a kit-of-parts.
- 7. (Previously presented) The combination preparation as claimed in claim 1, characterized in that the antilipemic (active compound component B) is selected from the group consisting of (a) HMG-CoA-reductase inhibitors; (b) squalene synthase inhibitors; (c) bile acid sequestrants; (d) fibric acid and its derivatives; (e) nicotinic acid and its analogs; (f) ω3-fatty acids.
- 8. (Previously presented) The combination preparation as claimed in claim 7, characterized in that the antilipemic (active compound component B) is an HMG-CoA-reductase inhibitor.
- 9. (Previously presented) The combination preparation as claimed in claim 8, characterized in that the antilipemic (active compound component B) is atorvastatin or its salt, hydrate, alkoxide, ester and tautomer.
- 10. (Previously presented) The combination preparation as claimed in claim 8, characterized in that the antilipemic (active compound component B) is cerivastatin or its salt, hydrate, alkoxide, ester and tautomer.
- 11. (Previously presented) The combination preparation as claimed in claim1, characterized in that the PDE inhibitor (active compound component A) is a cGMP PDE inhibitor and is selected from the group consisting of pyrazolopyrimidones of the general formula below

in which

R<sup>1</sup> represents hydrogen; C<sub>1</sub>-C<sub>3</sub>-alkyl; C<sub>1</sub>-C<sub>3</sub>-perfluoroalkyl; or C<sub>3</sub>-C<sub>5</sub>-cycloalkyl;

 $R^2$  denotes hydrogen;  $C_1$ - $C_6$ -alkyl, optionally substituted by  $C_3$ - $C_6$ -cycloalkyl;  $C_1$ - $C_3$ -perfluoroalkyl; or  $C_3$ - $C_6$ -cycloalkyl;

R<sup>3</sup> is C<sub>1</sub>-C<sub>6</sub>-alkyl, optionally substituted by C<sub>3</sub>-C<sub>6</sub>-cycloalkyl; C<sub>1</sub>-C<sub>6</sub>-perfluoroalkyl, C<sub>3</sub>-C<sub>5</sub>-cycloalkyl; C<sub>3</sub>-C<sub>6</sub>alkenyl; or C<sub>3</sub>-C<sub>6</sub>-alkinyl;

represents  $C_1$ - $C_4$ -alkyl, optionally substituted by OH,  $NR^5R^6$ , CN,  $CONR^5R^6$  or  $CO_2R^7$ ;  $C_2$ - $C_4$ -alkenyl, optionally substituted by CN,  $CONR^5R^6$  or  $CO_2R^7$ ;  $C_2$ - $C_4$ -alkanoyl, optionally substituted by  $NR^5R^6$ ; (hydroxy)- $C_2$ - $C_4$ -alkyl, optionally substituted by  $NR^5R^6$ ,  $(C_2$ - $C_3$ -alkoxy)- $C_1$ - $C_2$ -alkyl, optionally substituted by OH or  $NR^5R^6$ ,  $CO_2R^7$ ; halogen;  $NR^5R^6$ ,  $NHSO_2NR^5R^6$ ;  $NHSO_2R^8$ ;  $SO_2NR^9R^{10}$ ; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl, each of which is optionally substituted by methyl;

 $R^5$  and  $R^6$  each independently of one another denote hydrogen or  $C_1$ - $C_4$ -alkyl; or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino, 4- $N(R^{11})$ -piperazinyl or imidazolyl group, where this group is optionally substituted by methyl or OH;

 $R^7$  is hydrogen or  $C_1$ - $C_4$ -alkyl;

R<sup>8</sup> represents C<sub>1</sub>-C<sub>3</sub>-alkyl, optionally substituted by NR<sup>5</sup>R<sup>6</sup>;

R<sup>9</sup> and R<sup>10</sup> together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino, 4-N(R<sup>12</sup>)-piperazinyl group, where this group is optionally substituted by C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>3</sub>-alkoxy, NR<sup>13</sup>R<sup>14</sup> or CONR<sup>13</sup>R<sup>14</sup>;

- R<sup>11</sup> denotes hydrogen,  $C_1$ - $C_3$ -alkyl, optionally substituted by phenyl; (hydroxy)- $C_2$ - $C_3$ -alkyl; or  $C_1$ - $C_4$ -alkanoyl;
- R<sup>12</sup> is hydrogen,  $C_1$ - $C_6$ -alkyl,  $(C_1$ - $C_3$ -alkoxy)- $C_2$ - $C_6$ -alkyl; (hydroxy)- $C_2$ - $C_6$ -alkyl;  $(R^{13}R^{14}N)$ - $C_2$ - $C_6$ -alkyl;  $(R^{13}R^{14}NOC)$ - $C_1$ - $C_6$ -alkyl; CONR<sup>13</sup>R<sup>14</sup>; CSNR<sup>13</sup>R<sup>14</sup>, or C(NH)NR<sup>13</sup>R<sup>14</sup>; and
- $R^{13}$  and  $R^{14}$  each independently of one another represent hydrogen;  $C_1$ - $C_4$ -alkyl;  $(C_1$ - $C_3$ -alkoxy)- $C_2$ - $C_4$ -alkyl; or (hydroxy)- $C_2$ - $C_4$ -alkyl,

and their respective salts, hydrates, alkoxides and tautomers.

12. (Previously presented) The combination preparation as claimed in claim 1, characterized in that the PDE inhibitor (active compound component A) is a cGMP PDE inhibitor and is selected from the group consisting of 2-phenyl-substituted imidazotriazinones of the general formula

in which

- R<sup>1</sup> represents hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms;
- R<sup>2</sup> represents straight-chain alkyl having up to 4 carbon atoms;
- R³ and R⁴ are identical or different and represent hydrogen or represent straight-chain or branched alkenyl or alkoxy having in each case up to 8 carbon atoms, or represent a straight-chain or branched alkyl chain having up to 10 carbon atoms which is optionally interrupted by an oxygen atom and which is optionally mono- to polysubstituted by identical or different substituents from the group consisting of trifluoromethyl, trifluoromethoxy, hydroxyl, halogen, carboxyl, benzyloxycarbonyl, straight-chain or branched alkoxycarbonyl having up to 6 carbon atoms or by radicals of the formulae -SO₃H, -(A)a-NR<sup>7</sup>R<sup>8</sup>, -O-CO-NR<sup>7</sup>R<sup>8</sup>, -S(O)<sub>b</sub>-R<sup>9</sup>, -P(O)(OR<sup>10</sup>)(OR<sup>11</sup>),

in which

a and b are identical or different and represent a number 0 or 1,

- A represents a radical CO or SO<sub>2</sub>,
- R<sup>7</sup>, R<sup>8</sup> and R<sup>8</sup> are identical or different and represent hydrogen, or represent cycloalkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms, a 5- to 6-membered unsaturated, partially unsaturated or saturated optionally benzo-fused heterocycle having up to 3 heteroatoms from the group consisting of S, N and O, where the abovementioned ring systems are optionally mono- to polysubstituted by identical or different substituents from the group consisting of hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, carboxyl, halogen, straight-chain or branched alkoxy or alkoxycarbonyl having in each case up to 6 carbon atoms or by a group of the formula -(SO<sub>2</sub>)<sub>c</sub>-NR<sup>12</sup>R<sup>13</sup>,

in which

c represents a number 0 or 1,

R<sup>12</sup> and R<sup>13</sup> are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 5 carbon atoms,

or

R<sup>7</sup>, R<sup>8</sup> and R<sup>8</sup> represent straight-chain or branched alkoxy having up to 6 carbon atoms, or represent straight-chain or branched alkyl having up to 8 carbon atoms which is optionally mono- or polysubstituted by identical or different substituents from the group consisting of hydroxyl, halogen, aryl having 6 to 10 carbon atoms, straight-chain or branched alkoxy or alkoxycarbonyl having in each case up to 6 carbon atoms, or by a group of the formula -(CO)<sub>d</sub>-NR<sup>14</sup>R<sup>15</sup>,

in which

R<sup>14</sup> and R<sup>15</sup> are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms,

and

d represents a number 0 or 1,

or

R<sup>7</sup> and R<sup>8</sup> or R<sup>7</sup> and R<sup>8</sup> together with the nitrogen atom form a 5- to 7-membered saturated heterocycle which may optionally contain a further heteroatom from the group consisting of S and O or a radical of the formula -NR<sup>16</sup>,

in which

R<sup>16</sup> represents hydrogen, aryl having 6 to 10 carbon atoms, benzyl, a 5- to 7-membered aromatic or saturated heterocycle having up to 3 heteroatoms from the group consisting of S, N and O, which heterocycle is optionally substituted by methyl, or

represents straight-chain or branched alkyl having up to 6 carbon atoms which is optionally substituted by hydroxyl,

R<sup>9</sup> represents aryl having 6 to 10 carbon atoms, or represents straight-chain or branched alkyl having up to 4 carbon atoms,

R<sup>10</sup> and R<sup>11</sup> are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms,

or the alkyl chain listed above under R<sup>3</sup>/R<sup>4</sup> is optionally substituted by cycloalkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms or by a 5- to 7-membered partially unsaturated, saturated or unsaturated optionally benzo-fused heterocycle which may contain up to 4 heteroatoms from the group consisting of S, N; O or a radical of the formula -NR<sup>17</sup>.

in which

represents hydrogen, hydroxyl, formyl, trifluoromethyl, straight-chain or branched acyl or alkoxy having in each case up to 4 carbon atoms, or represents straight-chain or branched alkyl having up to 6 carbon atoms which is optionally mono- to polysubstituted by identical or different substituents from the group consisting of hydroxyl and straight-chain or branched alkoxy having up to 6 carbon atoms,

and where aryl and the heterocycle are optionally mono- to polysubstituted by identical or different substituents from the group consisting of nitro, halogen, -SO<sub>3</sub>H, straight-chain or branched alkyl or alkoxy having in each case up to 6 carbon atoms, hydroxyl, trifluoromethyl, trifluoromethoxy or by a radical of the formula -SO<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>,

in which

R<sup>18</sup> and R<sup>19</sup> are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms,

or

R<sup>3</sup> or R<sup>4</sup> represent a group of the formula -NR<sup>20</sup>R<sup>21</sup>,

in which

R<sup>20</sup> and R<sup>21</sup> have the meaning of R<sup>18</sup> and R<sup>19</sup> given above and are identical to or different from this meaning,

or

R<sup>3</sup> or R<sup>4</sup> represent adamantyl, or represent radicals of the formulae

$$H_3C$$
 $C_6H_5$ 
 $SO_2$ 
 $C_6H_5$ 
 $C_6H_5$ 

or represent cycloalkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms or represent a 5- to 7-membered partially unsaturated, saturated or unsaturated optionally benzo-fused heterocycle which may contain up to 4 heteroatoms from the group consisting of S, N; O or a radical of the formula -NR<sup>22</sup>,

in which

R<sup>22</sup> has the meaning of R<sup>16</sup> given above and is identical to or different from this meaning, or represents carboxyl, formyl or straight-chain or branched acyl having up to 5 carbon atoms,

and where cycloalkyl, aryl or the heterocycle are optionally mono- to polysubstituted by identical or different substituents from the group consisting of halogen, triazolyl, trifluoromethyl, trifluoromethoxy, carboxyl, straight-chain or branched acyl or alkoxycarbonyl having in each case up to 6 carbon atoms, nitro, or by groups of the formulae -SO<sub>3</sub>H, -OR<sup>23</sup>, (SO<sub>2</sub>)<sub>e</sub>NR<sup>24</sup>R<sup>25</sup>, -P(O)(OR<sup>26</sup>)(OR<sup>27</sup>),

in which

- e represents a number 0 or 1,
- R<sup>23</sup> represents a radical of the formula

represents cycloalkyl having 3 to 7 carbon atoms, or

represents hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms which is optionally substituted by cycloalkyl having 3 to 7 carbon atoms, benzyloxy, tetrahydropyranyl, tetrahydrofuranyl, straight-chain or branched alkoxy or alkoxycarbonyl having in each case up to 6 carbon atoms, carboxyl, benzyloxycarbonyl or phenyl which for its part may be mono- to polysubstituted by identical or different substituents from the group consisting of straight-chain or branched alkoxy having up to 4 carbon atoms, hydroxyl and halogen,

or alkyl is optionally substituted by radicals of the formulae -CO-NR<sup>28</sup>R<sup>29</sup> or -CO-R<sup>30</sup>,

in which

R<sup>28</sup> and R<sup>29</sup> are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 8 carbon atoms, or

 $R^{28}$  and  $R^{29}$  together with the nitrogen atom form a 5- to 7-membered saturated heterocycle which may optionally contain a further heteroatom from the group consisting of S and O,

and

R<sup>30</sup> represents phenyl or adamantyl,

R<sup>24</sup> and R<sup>25</sup> have the meaning of R<sup>18</sup> and R<sup>19</sup> given above and are identical to or different from this meaning,

 $R^{26}$  and  $R^{27}$  have the meaning of  $R^{10}$  and  $R^{11}$  given above and are identical to or different from this meaning

or cycloalkyl, aryl or the heterocycle are optionally substituted by straight-chain or branched alkyl having up to 6 carbon atoms which is optionally substituted by hydroxyl, carboxyl, by a 5-to 7-membered heterocycle having up to 3 heteroatoms from the group consisting of S, N and O or by groups of the formula -SO2-R31, P(O)(OR<sup>32</sup>)(OR<sup>33</sup>) or -NR<sup>34</sup>R<sup>35</sup>,

in which

R<sup>31</sup> is hydrogen or has the meaning of R<sup>9</sup> given above and is identical to or different from this meaning,

 $R^{32}$  and  $R^{33}$  have the meaning of  $R^{10}$  and  $R^{11}$  given above and are identical to or different from this meaning,

R<sup>34</sup> and R<sup>35</sup> are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms which is optionally substituted by hydroxyl or straight-chain or branched alkoxy having up to 4 carbon atoms, or

R<sup>34</sup> and R<sup>35</sup> together with the nitrogen atom form a 5- to 6-membered saturated heterocycle which may contain a further heteroatom from the group consisting of S and O or a radical of the formula -NR<sup>36</sup>,

in which

R<sup>36</sup> represents hydrogen, hydroxyl, straight-chain or branched alkoxycarbonyl having up to 7 carbon atoms or straight-chain or branched alkyl having up to 5 carbon atoms which is optionally substituted by hydroxyl,

or

R<sup>3</sup> and R<sup>4</sup> together with the nitrogen atom form a 5- to 7-membered unsaturated or saturated or partially unsaturated optionally benzo-fused heterocycle which may optionally contain up to 3 heteroatoms from the group consisting of S, N, O or a radical of the formula -NR<sup>37</sup>,

in which

represents hydrogen, hydroxyl, formyl, trifluoromethyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl having in each case up to 4 carbon atoms, or represents straight-chain or branched alkyl having up to 6 carbon atoms which is optionally mono- to polysubstituted by identical or different substituents from the group consisting of hydroxyl, trifluoromethyl, carboxyl, straight-chain or branched alkoxy or alkoxycarbonyl having in each case up to 6 carbon atoms or by groups of the formula - (D)<sub>f</sub>-NR<sup>38</sup>R<sup>39</sup>, -CO-(CH<sub>2</sub>)<sub>g</sub>-O-CO-R<sup>40</sup>, -CO-(CH<sub>2</sub>)<sub>h</sub>-OR<sup>41</sup> or -P(O)(OR<sup>42</sup>)(OR<sup>43</sup>),

in which

g and h are identical or different and represent a number 1, 2, 3 or 4,

and

- f represents a number 0 or 1,
- D represents a group of the formula -CO or -SO<sub>2</sub>,

R<sup>38</sup> and R<sup>39</sup> are identical or different and have the meaning of R<sup>7</sup> and R<sup>8</sup> given above,

R<sup>40</sup> represents straight-chain or branched alkyl having up to 6 carbon atoms,

R<sup>41</sup> represents straight-chain or branched alkyl having up to 6 carbon atoms,

R<sup>42</sup> and R<sup>43</sup> are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms,

or

R<sup>37</sup> represents a radical of the formula - (CO)<sub>i</sub>-E,

in which

- i represents a number 0 or 1,
- represents cycloalkyl having 3 to 7 carbon atoms or benzyl, represents aryl having 6 to 10 carbon atoms or a 5- to 6-membered aromatic heterocycle having up to 4 heteroatoms from the group consisting of S, N and O, where the ring systems listed above are optionally mono- to polysubstituted by identical or different substituents from the group consisting of nitro, halogen, SO<sub>3</sub>H, straight-chain or branched alkoxy having up to 6 carbon atoms, hydroxyl, trifluoromethyl, trifluoromethoxy or by a radical of the formula -SO<sub>2</sub>-NR<sup>44</sup>R<sup>45</sup>,

in which

R<sup>44</sup> and R<sup>45</sup> have the meaning of R<sup>18</sup> and R<sup>19</sup> given above and are identical to or different from this meaning,

or

E represents radicals of the formulae

and the heterocycle listed under R<sup>3</sup> and R<sup>4</sup>, which is formed together with the nitrogen atom, is optionally mono- to polysubstituted by identical or different substituents, if appropriate also geminally, by hydroxyl, formyl, carboxyl, straight-chain or branched acyl or alkoxycarbonyl having in each case up to 6 carbon atoms, nitro and groups of the formulae -P(O)(OR<sup>46</sup>)(OR<sup>47</sup>),

$$= NR^{48} \text{ or } -(CO)_{j}NR^{49}R^{50},$$

in which

 $R^{46}$  and  $R^{47}$  have the meaning of  $R^{10}$  and  $R^{11}$  given above and are identical to or different from this meaning,

R<sup>48</sup> is hydroxyl or straight-chain or branched alkoxy having up to 4 carbon atoms,

j is a number 0 or 1,

and

 $R^{49}$  and  $R^{50}$  are identical or different and have the meaning of  $R^{14}$  and  $R^{15}$  given above,

or the heterocycle listed under R<sup>3</sup> and R<sup>4</sup>, which is formed together with the nitrogen atom, is optionally substituted by straight-chain or branched alkyl having up to 6 carbon atoms which is optionally mono- to polysubstituted by identical or different substituents from the group consisting of hydroxyl, halogen, carboxyl, cycloalkyl or cycloalkyloxy having in each case 3 to 8 carbon atoms, straight-chain or branched alkoxy or alkoxycarbonyl having in each case up to 6 carbon atoms or by a radical of the formula -SO<sub>3</sub>H, -NR<sup>51</sup>R<sup>52</sup> or P(O)OR<sup>53</sup>OR<sup>54</sup>,

in which

R<sup>51</sup> and R<sup>52</sup> are identical or different and represent hydrogen, phenyl, carboxyl, benzyl or straightchain or branched alkyl or alkoxy having in each case up to 6 carbon atoms,

R<sup>53</sup> and R<sup>54</sup> are identical or different and have the meaning of R<sup>10</sup> and R<sup>11</sup> given above,

or the alkyl is optionally substituted by aryl having 6 to 10 carbon atoms which for its part may be mono- to polysubstituted by identical or different substituents from the group consisting of halogen, hydroxyl, straight-chain or branched alkoxy having up to 6 carbon atoms, or by a group of the formula -NR<sup>51</sup>'R<sup>52</sup>',


in which

 $R^{51}$ ' and  $R^{52}$ ' have the meaning of  $R^{51}$  and  $R^{52}$  given above and are identical to or different from this meaning,

or the heterocycle listed under R<sup>3</sup> and R<sup>4</sup>, which is formed together with the nitrogen atom, is optionally substituted by aryl having 6 to 10 carbon atoms or by a 5- to 7-membered saturated, partially unsaturated or unsaturated heterocycle having up to 3 heteroatoms from the group consisting of S, N and O, if appropriate also attached via an N-function, where the ring systems for their part may be substituted by hydroxyl or by straight-chain or branched alkyl or alkoxy having in each case up to 6 carbon atoms,

or

R<sup>3</sup> and R<sup>4</sup> together with the nitrogen atom form radicals of the formulae



R<sup>5</sup> and R<sup>6</sup> are identical or different and represent hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms, hydroxyl or represent straight-chain or branched alkoxy having up to 6 carbon atoms.

and their respective salts, hydrates, alkoxides and tautomers.

- 13. (Previously presented) The combination preparation as claimed in claim 1, characterized in that the PDE inhibitor (active compound component A) is a cGMP PDE inhibitor and is selected from the group consisting of (a) 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo-[4,3-d]-pyrimidin-7-one and its salts, hydrates, alkoxides and tautomers; and (b) 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f]-[1,2,4]-triazin-4-one and its salts, hydrates, alkoxides and tautomers.
- 14. (Previously presented) The combination preparation as claimed in claim 13, in that the PDE inhibitor (active compound component A) is 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo-[4,3-d]-pyrimidin-7-one citrate or 2-[2-ethoxy-5-(4-ethylpiperazine-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one hydrochloride trihydrate.
- 15. (Previously presented) A method for enhancing the activity of PDE inhibitors by administering an effective amount of an antilipemic.
- 16. (Previously presented) A method for the treatment of sexual dysfunction in men and women comprising administering to a host in need thereof an effective amount of the combination preparation of claim 1.
- 17. (Previously presented) The method of claim 16, characterized in that the antilipemic and the PDE inhibitor are administered either simultaneously or else successively.

- 18. (Currently amended) The method of claim 16, characterized in that the antilipemic and the PDE inhibitor are present as a functional unit, in particular in the form of wherein said unit is selected from a mixture, a mix or a blend.
- 19. (Currently amended) The method of claim 16, characterized in that the antilipemic and the PDE inhibitor are present (spatially) separated, in particular as a kit-of-parts.
- 20. (Previously presented) The method of claim 16, characterized in that the antilipemic is selected from the compounds defined in claims 7 to 10.
- 21. (Previously presented) The method of claim 16, characterized in that the PDE inhibitor is selected from the compounds defined in claims 11 to 14.
- 22. (Previously presented) The combination preparation of claim 1 characterized in that the PDE inhibitor is a cGMP PDE inhibitor.
- 23. (Previously presented) The combination preparation of claim 8, characterized in that the HMG-CoA-reductase inhibitor is a statin.
- 24. (Previously presented) The combination preparation of claim 23, characterized in that the statin is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, itavastatin, simvastatin and (+)-(3R,5S)-bis-(7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino)-pyrimidin-5-yl)-3,5-dihydroxy-6(E)-heptenoic acid, and their respective salts, hydrates, alkoxides, esters and tautomers.
- 25. (Previously presented) The method of claim 15, characterized in that the PDE inhibitor is a cGMP PDE inhibitor.
- 26. (Previously presented) The method of claim 16, characterized in that the sexual dysfunction is erectile dysfunction.